SCHEDULE: Vestal Point Capital Discloses 5% Stake in Bright Minds

Vestal Point Capital, LP and Ryan Wilder have filed a Schedule 13G reporting a 5% beneficial ownership stake in Bright Minds Biosciences Inc.

Summary

• Vestal Point Capital, LP and Ryan Wilder have reported beneficial ownership of 492,319 common shares of Bright Minds Biosciences Inc.
• The reported stake represents exactly 5% of the company's total outstanding common shares.
• The ownership calculation is based on 9,787,161 common shares outstanding as of February 12, 2026.
• The reporting persons maintain shared voting and dispositive power over the shares held by the Vestal Point Fund and Account.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure indicating institutional interest, which is neither inherently bullish nor bearish without further context on the firm's trading strategy.

Positives

• Institutional interest from Vestal Point Capital signals potential confidence in the company's long-term prospects.
• The filing confirms the acquisition was made in the ordinary course of business without intent to change or influence company control.

Negatives

• The disclosure of a 5% threshold may lead to increased volatility if the market perceives the position as a precursor to future divestment or activist pressure.

Risks

• The investment is subject to market fluctuations in the biotechnology sector.
• The reporting persons have disclaimed any intent to influence control, but changes in investment strategy could alter this stance in the future.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the company's operations, but confirms the reporting persons hold the shares for investment purposes in the ordinary course of business.

Management Comments

• The reporting persons certify that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional filings of this nature are standard in the biotechnology sector, where specialized investment firms often take significant positions in small-cap firms to capitalize on clinical trial milestones or pipeline developments.

Comparison to Industry Standards

• The filing follows standard SEC regulatory requirements for institutional investors crossing the 5% ownership threshold.
• The use of a Joint Filing Agreement is consistent with industry practice for investment managers and their principals.

Stakeholder Impact

• Shareholders may view the entry of an institutional investor as a validation of the company's valuation.
• The company's management may need to engage with the new significant shareholder regarding future strategic direction.

Next Steps

• The reporting persons are required to file amendments to this Schedule 13G if there are material changes in their percentage of ownership.

Key Dates

Keywords

Bright Minds Biosciences, Schedule 13G, Vestal Point Capital, Beneficial Ownership, Biotech Investment, Institutional Holdings